News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Mammen Mathai
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/16/2023 |
4
| Mammen Mathai (Director) has filed a Form 4 on 10x Genomics, Inc.|
Txns:
| Granted 1,865 shares
@ $0
Granted 4,661 options to buy
@ $57.62, valued at
$268.6k
|
|
| 05/15/2023 |
4
| Mammen Mathai (Director) has filed a Form 4 on 10x Genomics, Inc.|
Txns:
| Sold 33,000 shares
@ $52.8208, valued at
$1.7M
Exercised 200,000 options to buy
@ $1.16, valued at
$232k
|
|
| 05/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/17/2022 |
4
| Mammen Mathai (Director) has filed a Form 4 on 10x Genomics, Inc.|
Txns:
| Granted 2,120 shares
@ $0
Granted 5,300 options to buy
@ $39.62, valued at
$210k
|
|
| 02/17/2022 |
4
| Mammen Mathai (EVP, Pharm, R&D) has filed a Form 4 on JOHNSON & JOHNSON|
Txns:
| Paid exercise price by delivering 3,366 shares
@ $165.89, valued at
$558.4k
Granted 38,736 options to buy
@ $165.89, valued at
$6.4M
Granted 3,922 options to buy
@ $0
Exercised 7,740 options to buy
@ $0 |
|
| 02/15/2022 |
4
| Mammen Mathai (EVP, Pharm, R&D) has filed a Form 4 on JOHNSON & JOHNSON|
Txns:
| Paid exercise price by delivering 2,335 shares
@ $168.85, valued at
$394.3k
Exercised 7,418 options to buy
@ $0 |
|
| 01/13/2022 |
3
| Mammen Mathai (EVP, Pharm, R&D) has filed a Form 3 on JOHNSON & JOHNSON |
| 06/15/2021 |
4
| Mammen Mathai (Director) has filed a Form 4 on 10x Genomics, Inc.|
Txns:
| Granted 625 shares
@ $0
Granted 1,563 options to buy
@ $193.51, valued at
$302.5k
|
|
| 06/17/2020 |
4
| Mammen Mathai (Director) has filed a Form 4 on 10x Genomics, Inc.|
Txns:
| Granted 4,432 options to buy
@ $88.42, valued at
$391.9k
|
|
| 09/16/2019 |
4
| Mammen Mathai (Director) has filed a Form 4 on 10x Genomics, Inc.|
Txns:
| Disposed of 200,000 options to buy
@ $1.16, valued at
$232k
Acquired 200,000 options to buy
@ $1.16, valued at
$232k
|
|
| 09/11/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 03/17/2016 |
4
| Mammen Mathai (SVP, Research & Development) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Granted 90,000 shares
@ $0 |
|
| 02/23/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 11/24/2015 |
4
| Mammen Mathai (SVP, Research & Development) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 934 shares
@ $17.17, valued at
$16k
|
|
| 08/24/2015 |
4
| Mammen Mathai (SVP, Research & Development) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 934 shares
@ $12.98, valued at
$12.1k
|
|
| 06/04/2015 |
4
| Mammen Mathai (SVP, Research & Development) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 7,360 shares
@ $13.83, valued at
$101.8k
|
|
| 05/22/2015 |
4
| Mammen Mathai (SVP, Research & Development) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 673 shares
@ $14.24, valued at
$9.6k
|
|
| 02/24/2015 |
4
| Mammen Mathai (SVP, Research & Development) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 674 shares
@ $19.52, valued at
$13.2k
|
|
| 02/09/2015 |
4
| Mammen Mathai (SVP, Research & Development) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Granted 130,000 shares
@ $0 |
|
| 11/24/2014 |
4
| Mammen Mathai (SVP, Research & Early Clin Dev) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 658 shares
@ $0 |
|
| 10/10/2014 |
4
| Mammen Mathai (SVP, Research & Early Clin Dev) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Granted 170,000 options to buy
@ $22, valued at
$3.7M
|
|
| 08/22/2014 |
4
| Mammen Mathai (SVP, Research & Early Clin Dev) has filed a Form 4 on THERAVANCE INC|
Txns:
| Paid exercise price by delivering 3,261 shares
@ $22.76, valued at
$74.2k
|
|
| 06/18/2014 |
4
| Mammen Mathai (SVP, Research & Early Clin Dev) has filed a Form 4 on THERAVANCE INC|
Txns:
| Granted 28,365 shares
@ $0 |
|
| 06/04/2014 |
4
| Mammen Mathai (SVP, Research & Early Clin Dev) has filed a Form 4 on THERAVANCE INC|
Txns:
| Granted 50,000 shares
@ $0
Granted 21,000 shares
@ $0
Granted 50,000 shares
@ $0 |
|
| 05/12/2014 |
4
| Mammen Mathai (SVP, Research & Early Clin Dev) has filed a Form 4 on THERAVANCE INC|
Txns:
| Paid exercise price by delivering 22,833 shares
@ $26.86, valued at
$613.3k
Gifted 1,200 shares
@ $0 |
|
| 04/29/2014 |
4
| Mammen Mathai (SVP, Research & Early Clin Dev) has filed a Form 4 on THERAVANCE INC|
Txns:
| Granted 37,500 shares
@ $0 |
|
| 03/10/2014 |
4
| Mammen Mathai (SVP, Research & Early Clin Dev) has filed a Form 4 on THERAVANCE INC|
Txns:
| Exercised 12,903 options to buy
@ $12.4, valued at
$160k
Exercised 29,250 options to buy
@ $16, valued at
$468k
|
|
| 02/24/2014 |
4
| Mammen Mathai (SVP, Research & Early Clin Dev) has filed a Form 4 on THERAVANCE INC|
Txns:
| Paid exercise price by delivering 4,307 shares
@ $39.98, valued at
$172.2k
|
|
| 02/19/2014 |
4
| Mammen Mathai (SVP, Research & Early Clin Dev) has filed a Form 4 on THERAVANCE INC|
Txns:
| Sold 30,400 shares
@ $39.26, valued at
$1.2M
Sold 4,600 shares
@ $40.04, valued at
$184.2k
|
|
| 11/22/2013 |
4
| Mammen Mathai (SVP, Research & Early Clin Dev) has filed a Form 4 on THERAVANCE INC|
Txns:
| Paid exercise price by delivering 4,569 shares
@ $36.4, valued at
$166.3k
|
|
| 08/22/2013 |
4
| Mammen Mathai (SVP, Research & Early Clin Dev) has filed a Form 4 on THERAVANCE INC|
Txns:
| Paid exercise price by delivering 3,813 shares
@ $35.89, valued at
$136.8k
Exercised 18,750 options to buy
@ $16, valued at
$300k
|
|
| 08/01/2013 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 07/26/2013 |
4
| Mammen Mathai (SVP, Research & Early Clin Dev) has filed a Form 4 on THERAVANCE INC|
Txns:
| Granted 5,000 shares
@ $0 |
|
| 05/31/2013 |
4
| Mammen Mathai (SVP, Research & Early Clin Dev) has filed a Form 4 on THERAVANCE INC|
Txns:
| Exercised 4,570 options to buy
@ $3.1, valued at
$14.2k
Exercised 6,451 options to buy
@ $12.4, valued at
$80k
|
|
|
|
|